Table 2. Studies that evaluation the efficacy of plasma therapy in COVID-19 patients.
| References | n/CP sample | Antibody titer | CP dose (mL) |
Viral charge (x10 ^/dL) |
Previous treatments | Hospitalization (variation) |
Adverse events (n) |
Mortality rate reduction |
|---|---|---|---|---|---|---|---|---|
| Abolghasemi et al.(36) | 189/115 CP versus 74 ST | Plasma antibody titer cut off index >1.1 | 2x500mL | NI | ST + antiviral (LPV/Rit), HydChl and anti-inflammatory agent | 9.54 days CP versus 12.88 days ST CP reduced length of stay by ~26% | ~1% CP Transient mild fever and chills following infusion of the plasma (n=1) | 14.8% CP versus 24.3% ST ~40% |
| Li et al.(37) | 103/52 CP (23 severe + 29 life-threatening) versus 51 ST (22 severe + 29 life-threatening) | 1:350 (6 donors) | 4-13mL/kg | Reduction in severe patients: 44.7% (24 hours), 68.1% (48 hours) and 87.2% (72 hours) virus-free Life-threatening patients: 53.8% (24 hours); 73.1 (48 hours) and 84.6% (72 hours) virus-free | Antiviral (41/46; 89.1%); antibacterial (38/46; 82.6%); Chinese herbal medicine (26/46; 56.5%); steroids (21/46 45.7%); antifungal (15/46; 32.6%); HIg (13/46; 28.3%); interferon (12/46; 26.1%) | Severe: 32.00 (26.00-40.00); life-threatening: indeterminate (46.00-indeterminate) | ~4% CP Chills and rashes within 2 hours (n=1); shortness of breath, cyanosis and severe dyspnea within 6 hours (n=1) | 15.7% CP versus 24.0% ST ~35% |
| Xia et al.(38) | 1,568/138 | Not significantly higher in rapid responders than in moderate responders | 200-1,200mL | 20/25 (80%) became virus-free after 14 days | NI | 2.4% CP versus 5.1% ST CP reduced admitted to the ICU by ~53% | ~2% CP Pruritus or erythema during transfusion (n=3) | 2.2% CP versus 4.1% ST ~50% |
CP: convalescent plasma; ST: standard treatment; NI: not informed; LPV: lopinavir; Rit: ritonavir; HydChl: hydroxychloroquine; HIg: human immunoglobulin; ICU: intensive care unit.